查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1496009

全球细胞采集市场 - 2024 年至 2029 年预测

Global Cell Harvesting Market - Forecasts from 2024 to 2029
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 114 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

细胞采集市场预计将从2022年的20.88亿美元成长到2029年的210.9亿美元，复合年增长率为39.15%。

预计在预测期内推动市场成长的主要原因是患者中癌症和残疾病例数量的增加。根据世界卫生组织（WHO）资料，2020年全球新诊断主流癌症病例超过1,010万例。同年该疾病导致超过 5,019,000 人死亡。细胞采集和细胞治疗是预计将推动市场成长的主要癌症治疗方法。

此外，医疗保健和健康研发支出的增加导致了早期检测和更好治疗的产品创新，预计这将扩大市场范围。此外，预计意识的提高将支持预测期内的市场成长。癌症是一种全球性疾病，但生存机率因地区的医疗基础设施和意识而异。

根据世界卫生组织的资料，在已开发国家，诊断出癌症的患者的存活率约为90%。印度的存活率低至 66%，南非的存活率较低，为 40%。在已开发国家，已证实早期发现和治疗可以提高患者的存活率。然而，在开发中国家，适当的治疗对存活率有重大影响。

细胞移植和细胞疗法是用于治癒患有特定癌症类型和细胞疾病的患者的典型治疗方法。根据盖尔研究所的资料，干细胞疗法对 45% 的治疗患者有效。技术进步预计将提高功效并为细胞采集市场带来显着成长。由于该地区医疗旅游业的兴起，预计亚太地区细胞采集市场将呈指数级增长。

市场驱动因素：

  • 癌症患者数量的增加和健康意识的增加预计将推动市场成长。

推动细胞采集市场成长的主要原因是癌症患者数量的增加。根据世界卫生组织关于乳癌的报告，2020年全球将有230万名女性被诊断出罹患乳癌，全球将有780万人受到乳癌的影响。同年，685,000 名女性死于乳癌，使其成为女性癌症死亡的主要原因。

此外，新增肺癌确诊病例221万例，新增大肠直肠癌确诊193万例。这两种类型是癌症死亡的主要原因，2020 年分别夺走 180 万人和 935,000 人的生命。皮肤癌新增病例也达 120 万人。对病例数量不断增加以及生活方式日益复杂的严重担忧导致对早期诊断的投资增加。已经证实，早期诊断可以提高患者的存活率并降低癌症死亡率。

此外，细胞疗法是治疗乳癌、大肠癌和皮肤癌的有效治疗方法。过去 30 年来，高所得国家的大量投资已将癌症死亡率降低了 40%。此外，世界卫生组织估计，在 2020 年至 2040 年间，每年将癌症死亡率降低 2-4%，可避免 250 万人死于乳癌。

在 GBCI 的领导下，该组织旨在透过更好的医疗技术和基础设施来提高意识并鼓励早期检测实践。此外，该组织的目标是建立集中的诊断和治疗服务，以取得更好的结果。预计投资的增加将推动市场对细胞采集技术的需求。

市场限制因素：

  • 细胞治疗的高成本可能会阻碍细胞采集产业的市场规模。

细胞采集市场面临的主要限制之一是细胞治疗的成本极高。细胞采集装置用于细胞治疗，从捐赠者或患者身上收集细胞。然而，细胞疗法既昂贵又耗时。高昂的费用和时间浪费使患者不愿意选择这种治疗方法。此外，化疗和手术等更便宜的替代疗法的可用性也阻碍了市场的成长。

主要进展

  • 2022 年 9 月 - Thermo Fisher Scientific 推出专为大规模细胞培养物收集而设计的 DynaSpin 抛弃式离心系统。该系统透过减少所需的深度过滤筒的数量来简化收穫，从而与传统收穫系统相比，获得相似或更高的产品产量。 DynaSpin 系统还提高了生技药品製造的营运效率、成本节约和永续实践。消除了 70% 的废弃物，所需材料减少了 6 倍。该系统还融合了一次性产品的优点，包括可扩展性、快速转换、减少停机时间和降低污染风险。 DynaSpin 目前可在全球购买。
  • 2022 年 6 月—雪梨科技大学和 Regeneus 的研究人员开发了一种 3D 列印微流体干细胞采集装置，为处理干细胞提供了一种经济有效且可扩展的方法。研究团队开发了一种3D列印的微流体干细胞采集装置，能够从反应器中高品质、广泛地生产干细胞。这项技术整合了D列印和微流体技术，有望使干细胞疗法以更低的成本得到更广泛的应用。该系统目前处于原型阶段，可处理间质干细胞，它可以分裂并分化成多种组织细胞。
  • 2022 年 6 月 - 根据内分泌学会年会 ENDO2022 上进行的一项临床研究，建议将一种名为 PEC-Direct 的干细胞治疗方法用于替代胰腺，用于 1 型糖尿病高风险患者。在这项研究中，使用这种新治疗方法的几名患者的 C胜肽（一种与胰岛素一起在胰腺中产生的物质）出现了临床相关的增加。 PEC-Direct 装置提供长期、稳定的胰岛素来源来调节血糖浓度，适用于容易出现急性併发症的高风险 1 型糖尿病患者。
  • 2022 年 6 月 - Meso Numismatics, Inc. 与 Ramzan Ali 干细胞中心签署了一项为期五年的协议，以扩大其在全球第五大人口医疗保健市场巴基斯坦的服务。此次合作旨在透过建立细胞治疗卓越中心来扩大全球干细胞集团的品牌，以满足亚洲和中东市场的需求。该合作伙伴关係将建立一个医疗技术中心，涵盖五个城市的医疗培训，举办年度会议以提高人们对细胞疗法益处的认识，并推出 GSCG 的细胞产品，例如 CELLGENIC胞外体系列。

主要市场区隔：

依收藏类型

  • 手动细胞采集
  • 自动细胞采集

依干细胞类型

  • 脐带干细胞
  • 成体干细胞
  • 胎儿干细胞
  • 胚胎干细胞
  • 其他的

按用途

  • 癌症
  • 血液疾病
  • 遗传疾病
  • 其他的

按最终用户

  • 生物技术和生物製药公司
  • 医院
  • 研究中心

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 其他的
  • 中东/非洲中东/非洲
  • UAE
  • 沙乌地阿拉伯
  • 其他的
  • 亚太地区
  • 日本
  • 中国
  • 印度
  • 韩国
  • 台湾
  • 泰国
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关利益者的主要利益

第二章调查方法

  • 研究设计
  • 调查过程

第三章执行摘要

  • 主要发现

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析
  • 分析师观点

第五章全球细胞收穫市场：依收穫类型

  • 介绍
  • 手动细胞采集
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 自动细胞采集
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第六章全球细胞采集市场：依干细胞类型

  • 介绍
  • 脐带干细胞
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 成体干细胞
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 胎儿干细胞
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 胚胎干细胞
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第七章 全球细胞采集市场：依应用分类

  • 介绍
  • 癌症
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 血液疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 遗传疾病
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 其他的
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第八章全球细胞收穫市场：依最终用户分类

  • 介绍
  • 生物技术和生物製药公司
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 医院
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力
  • 研究中心
    • 市场机会和趋势
    • 成长前景
    • 地域获利能力

第九章全球细胞收穫市场：按地区

  • 介绍
  • 北美洲
    • 按收穫类型
    • 依干细胞类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 南美洲
    • 按收穫类型
    • 依干细胞类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 欧洲
    • 按收穫类型
    • 依干细胞类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 中东/非洲
    • 按收穫类型
    • 依干细胞类型
    • 按用途
    • 按最终用户
    • 按国家/地区
  • 亚太地区
    • 按收穫类型
    • 依干细胞类型
    • 按用途
    • 按最终用户
    • 按国家/地区

第十章竞争环境及分析

  • 主要企业及策略分析
  • 市场占有率分析
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十一章 公司简介

  • PerkinElmer Inc.
  • Tomtec
  • CTIBiotech
  • RegenMed Systems Inc.
  • Aspire Medical Innovation
  • Sartorius AG
  • Terumo Corporation
简介目录
Product Code: KSI061611917

The global cell harvesting market is projected to witness a compound annual growth rate of 39.15% to grow to US$21.090 billion by 2029, from US$2.088 billion in 2022.

The prime reason that is expected to drive the market growth during the forecasted period is the rising cases of cancers and disorders among patients. Data from the World Health Organization (WHO) shows that in 2020, more than 10.1 million new cases of mainstream cancer were diagnosed globally. The disease led to more than 5.019 million deaths in the year. Cell harvesting and cell therapy are leading cancer treatments that are expected to drive market growth.

Moreover, increasing expenditure in healthcare and health research and development has led to the innovation of products for early detection and superior treatment, which is expected to increase the market scope. Furthermore, increasing awareness is projected to support the market growth during the forecasted period. While cancer is a global disease, different regions have different survival chances based on the healthcare infrastructure and awareness.

Data from WHO shows that survival chances for a patient diagnosed with cancer range around 90% in developed nations. In India, the survival chance is as low as 66% while in South Africa, it is even lower to 40%. It has been observed that early detection and treatment in developed nations successfully increase the survival chances of patients. However, in developing nations, adequate treatment significantly affects the survival chances.

Cell transplant and cell therapy are leading treatments that are used to cure a patient with certain cancer types and cell disorders. Data from The Guyer Institute shows that stem cell therapy is effective in 45% of the treated patients. Advancement in technology is expected to increase the effectiveness and hence provide substantial growth for the cell harvesting market. The Asia Pacific cell harvesting market is projected to grow at an exponential rate owing to increasing medical tourism in the region.

Market Drivers:

  • Increasing cancer cases and health consciousness are anticipated to surge the market growth.

The prime reason driving the market growth of the cell harvesting market is the rising cases of cancer. WHO report on breast cancer shows that in 2020, 2.3 million women globally were diagnosed with breast cancer, adding to a total active case of 7.8 million worldwide. 685,000 women died of breast cancer in the year, making it one of the leading cancer-causing death diseases among women.

Additionally, 2.21 million new cases of lung cancer were diagnosed while 1.93 million new cases of colon and rectum cancer were discovered. These two types were the leading cause of cancer deaths, taking 1.80 million lives and 0.935 million lives, respectively, in 2020. The skin was another leading cancer with 1.20 million new cases. Complex lifestyles along with increasing complexities have raised serious concerns about rising cases, leading to higher investment in early diagnosis. It has been observed that early diagnosis increases the survival chance of the patient and hence reduces cancer mortality.

Furthermore, cell therapy is an effective treatment to cure breast, colon rectum, and skin cancer. Substantial investment by higher-income countries has led to the successful reduction of cancer mortality by 40% in the past 3 decades. Furthermore, WHO estimates that a reduction of cancer mortality by 2-4% per year between 2020 to 2040 will avoid 2.5 million potential breast cancer deaths.

Under GBCI, the organization aims to increase awareness and encourage early detection practice through better healthcare technology and infrastructure. Furthermore, the organization aims to establish centralized services for diagnosis and treatment for better results. The rising investment is expected to drive the market demand for cell harvesting technology.

Market Restraint:

  • The significant cost of cell therapy could hinder the market size of the cell harvesting industry.

One of the prime constraints faced by the cell harvesting market is the significantly high cost of cell therapy treatment. Cell harvesting devices are used in cell therapy treatment for the extraction of cells from donors or patients. However, cell therapy treatment is an expensive procedure and takes time. High cost and time utilization discourage patients to opt for this treatment. Furthermore, the availability of less expensive substitutes such as chemotherapy and surgery, in cancer hinders the market growth.

Key Developments:

  • September 2022- Thermo Fisher Scientific introduced the DynaSpin Single-Use Centrifuge system, designed for large-scale cell culture harvesting. The system streamlines harvesting by reducing the number of depth filtration cartridges needed, resulting in equivalent or improved product yield compared to traditional harvest systems. The DynaSpin system also offers operational efficiency, cost savings, and sustainable practices in biologics production. It eliminates 70% of waste and offers a six-fold reduction in material requirements. The system also incorporates advantages of single-use products, including scalability, rapid change over, reduced downtime, and lower risk of contamination. The DynaSpin is now available globally for purchase.
  • June 2022- Researchers from the University of Technology Sydney and Regeneus developed a 3D-printed microfluidic stem cell harvester, offering a cost-effective, scalable method for processing stem cells. They have developed a 3D-printed microfluidic stem cell harvester, allowing for high-quality, wide-scale production of stem cells from bioreactors. The technology, which integrates 3D printing and microfluidics, expected to make stem cell therapies more widely available at a lower cost. The system, currently in the prototype stage, processes mesenchymal stem cells, which can divide and differentiate into multiple tissue cells. The researchers are working closely with biotechnology companies to commercialize the innovative technology.
  • June 2022- A clinical study at ENDO 2022, the Endocrine Society's annual meeting suggests that stem cell-based therapy called PEC-Direct, designed to replace the pancreas, could potentially provide blood sugar control in patients with high-risk type 1 diabetes. The study found that multiple patients using the new treatment had clinically relevant increases in C-peptide, a substance made in the pancreas along with insulin. The PEC-Direct device provides a long-term, stable source of insulin to regulate glucose levels, and is intended for patients with high-risk type 1 diabetes who may be vulnerable to acute complications.
  • June 2022- Meso Numismatics, Inc. signed a 5-year contract with Ramzan Ali Stem Cell Center to expand its services in Pakistan, the world's 5th most populous healthcare market. The partnership aims to expand the Global Stem Cell Group brand by creating excellence centers in cell therapy to meet demand in Asian and Middle Eastern markets. The alliance established a medical technology center, cover medical training in five cities, hold an annual congress to raise awareness of cellular medicine benefits, and launch GSCG's cellular products, such as the CELLGENIC line of exosomes.

Key Market Segments:

By Harvesting Type

  • Manual Cell Harvesting
  • Automated Cell Harvesting

By Stem Cell Type

  • Umbilical Cord Stem Cells
  • Adult Stem Cells
  • Fetal Stem Cells
  • Embryonic Stem Cells
  • Others

By Application

  • Cancer
  • Blood Disorder
  • Genetic Disorder
  • Others

By End Users

  • Biotechnology & Biopharmaceutical Companies
  • Hospitals
  • Research Centers

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • Spain
  • France
  • Others
  • Middle East and Africa
  • UAE
  • Saudi Arabia
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline
  • 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Processes

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis
  • 4.5. Analyst View

5. GLOBAL CELL HARVESTING MARKET, BY HARVESTING TYPE

  • 5.1. Introduction
  • 5.2. Manual Cell Harvesting
    • 5.2.1. Market Opportunities and Trends
    • 5.2.2. Growth Prospects
    • 5.2.3. Geographic Lucrativeness
  • 5.3. Automated Cell Harvesting
    • 5.3.1. Market Opportunities and Trends
    • 5.3.2. Growth Prospects
    • 5.3.3. Geographic Lucrativeness

6. GLOBAL CELL HARVESTING MARKET, BY STEM CELL TYPE

  • 6.1. Introduction
  • 6.2. Umbilical Cord Stem Cells
    • 6.2.1. Market Opportunities and Trends
    • 6.2.2. Growth Prospects
    • 6.2.3. Geographic Lucrativeness
  • 6.3. Adult Stem Cells
    • 6.3.1. Market Opportunities and Trends
    • 6.3.2. Growth Prospects
    • 6.3.3. Geographic Lucrativeness
  • 6.4. Fetal Stem Cells
    • 6.4.1. Market Opportunities and Trends
    • 6.4.2. Growth Prospects
    • 6.4.3. Geographic Lucrativeness
  • 6.5. Embryonic Stem Cells
    • 6.5.1. Market Opportunities and Trends
    • 6.5.2. Growth Prospects
    • 6.5.3. Geographic Lucrativeness
  • 6.6. Others
    • 6.6.1. Market Opportunities and Trends
    • 6.6.2. Growth Prospects
    • 6.6.3. Geographic Lucrativeness

7. GLOBAL CELL HARVESTING MARKET, BY APPLICATION

  • 7.1. Introduction
  • 7.2. Cancer
    • 7.2.1. Market Opportunities and Trends
    • 7.2.2. Growth Prospects
    • 7.2.3. Geographic Lucrativeness
  • 7.3. Blood Disorder
    • 7.3.1. Market Opportunities and Trends
    • 7.3.2. Growth Prospects
    • 7.3.3. Geographic Lucrativeness
  • 7.4. Genetic Disorder
    • 7.4.1. Market Opportunities and Trends
    • 7.4.2. Growth Prospects
    • 7.4.3. Geographic Lucrativeness
  • 7.5. Others
    • 7.5.1. Market Opportunities and Trends
    • 7.5.2. Growth Prospects
    • 7.5.3. Geographic Lucrativeness

8. GLOBAL CELL HARVESTING MARKET, BY END USERS

  • 8.1. Introduction
  • 8.2. Biotechnology & Biopharmaceutical Companies
    • 8.2.1. Market Opportunities and Trends
    • 8.2.2. Growth Prospects
    • 8.2.3. Geographic Lucrativeness
  • 8.3. Hospitals
    • 8.3.1. Market Opportunities and Trends
    • 8.3.2. Growth Prospects
    • 8.3.3. Geographic Lucrativeness
  • 8.4. Research Centers
    • 8.4.1. Market Opportunities and Trends
    • 8.4.2. Growth Prospects
    • 8.4.3. Geographic Lucrativeness

9. GLOBAL CELL HARVESTING MARKET, BY GEOGRAPHY

  • 9.1. Introduction
  • 9.2. North America
    • 9.2.1. By Harvesting Type
    • 9.2.2. By Stem Cell Type
    • 9.2.3. By Application
    • 9.2.4. By End Users
    • 9.2.5. By Country
      • 9.2.5.1. USA
        • 9.2.5.1.1. Market Opportunities and Trends
        • 9.2.5.1.2. Growth Prospects
      • 9.2.5.2. Canada
        • 9.2.5.2.1. Market Opportunities and Trends
        • 9.2.5.2.2. Growth Prospects
      • 9.2.5.3. Mexico
        • 9.2.5.3.1. Market Opportunities and Trends
        • 9.2.5.3.2. Growth Prospects
  • 9.3. South America
    • 9.3.1. By Harvesting Type
    • 9.3.2. By Stem Cell Type
    • 9.3.3. By Application
    • 9.3.4. By End Users
    • 9.3.5. By Country
      • 9.3.5.1. Brazil
        • 9.3.5.1.1. Market Opportunities and Trends
        • 9.3.5.1.2. Growth Prospects
      • 9.3.5.2. Argentina
        • 9.3.5.2.1. Market Opportunities and Trends
        • 9.3.5.2.2. Growth Prospects
      • 9.3.5.3. Others
        • 9.3.5.3.1. Market Opportunities and Trends
        • 9.3.5.3.2. Growth Prospects
  • 9.4. Europe
    • 9.4.1. By Harvesting Type
    • 9.4.2. By Stem Cell Type
    • 9.4.3. By Application
    • 9.4.4. By End Users
    • 9.4.5. By Country
      • 9.4.5.1. United Kingdom
        • 9.4.5.1.1. Market Opportunities and Trends
        • 9.4.5.1.2. Growth Prospects
      • 9.4.5.2. Germany
        • 9.4.5.2.1. Market Opportunities and Trends
        • 9.4.5.2.2. Growth Prospects
      • 9.4.5.3. Spain
        • 9.4.5.3.1. Market Opportunities and Trends
        • 9.4.5.3.2. Growth Prospects
      • 9.4.5.4. France
        • 9.4.5.4.1. Market Opportunities and Trends
        • 9.4.5.4.2. Growth Prospects
      • 9.4.5.5. Others
        • 9.4.5.5.1. Market Opportunities and Trends
        • 9.4.5.5.2. Growth Prospects
  • 9.5. Middle East and Africa
    • 9.5.1. By Harvesting Type
    • 9.5.2. By Stem Cell Type
    • 9.5.3. By Application
    • 9.5.4. By End Users
    • 9.5.5. By Country
      • 9.5.5.1. UAE
        • 9.5.5.1.1. Market Opportunities and Trends
        • 9.5.5.1.2. Growth Prospects
      • 9.5.5.2. Saudi Arabia
        • 9.5.5.2.1. Market Opportunities and Trends
        • 9.5.5.2.2. Growth Prospects
      • 9.5.5.3. Others
        • 9.5.5.3.1. Market Opportunities and Trends
        • 9.5.5.3.2. Growth Prospects
  • 9.6. Asia Pacific
    • 9.6.1. By Harvesting Type
    • 9.6.2. By Stem Cell Type
    • 9.6.3. By Application
    • 9.6.4. By End Users
    • 9.6.5. By Country
      • 9.6.5.1. Japan
        • 9.6.5.1.1. Market Opportunities and Trends
        • 9.6.5.1.2. Growth Prospects
      • 9.6.5.2. China
        • 9.6.5.2.1. Market Opportunities and Trends
        • 9.6.5.2.2. Growth Prospects
      • 9.6.5.3. India
        • 9.6.5.3.1. Market Opportunities and Trends
        • 9.6.5.3.2. Growth Prospects
      • 9.6.5.4. South Korea
        • 9.6.5.4.1. Market Opportunities and Trends
        • 9.6.5.4.2. Growth Prospects
      • 9.6.5.5. Taiwan
        • 9.6.5.5.1. Market Opportunities and Trends
        • 9.6.5.5.2. Growth Prospects
      • 9.6.5.6. Thailand
        • 9.6.5.6.1. Market Opportunities and Trends
        • 9.6.5.6.2. Growth Prospects
      • 9.6.5.7. Indonesia
        • 9.6.5.7.1. Market Opportunities and Trends
        • 9.6.5.7.2. Growth Prospects
      • 9.6.5.8. Others
        • 9.6.5.8.1. Market Opportunities and Trends
        • 9.6.5.8.2. Growth Prospects

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 10.1. Major Players and Strategy Analysis
  • 10.2. Market Share Analysis
  • 10.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 10.4. Competitive Dashboard

11. COMPANY PROFILES

  • 11.1. PerkinElmer Inc.
  • 11.2. Tomtec
  • 11.3. CTIBiotech
  • 11.4. RegenMed Systems Inc.
  • 11.5. Aspire Medical Innovation
  • 11.6. Sartorius AG
  • 11.7. Terumo Corporation